Imugene Limited (ASX: IMU)
Health Care · Biotechnology · AU
AU$0.08
-3.53% today · -69.1% 1Y
Imugene Limited (ASX: IMU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.78M and employs 15 people.
Over the last twelve months the share price has lost 69.1%, trading between 0.08 and 0.46.
Tweenvest scores Imugene Limited across four factors: quality 29/100, value 50/100. Its strongest factor is value.
IMU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.78M
- Revenue (TTM)
- $2.63M
- P/E
- —
- EPS
- -0.23
- Dividend yield
- —
- Beta (5Y)
- 2.09
- 52-week high
- AU$0.46
- 52-week low
- AU$0.08
- Avg volume (3M)
- —
- Shares outstanding
- 489.72M
- Employees
- 15
- Next earnings
- —
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
- ISIN
- AU000000IMU9
- Listed since
- Dec 30, 1993
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.